Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04109352
Other study ID # CE0783.19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date December 2022

Study information

Verified date October 2021
Source University of Virginia
Contact Margaret N Kosek, MD
Phone 434-243-9552
Email mkosek@virginia.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Linear growth failure, a manifestation of chronic undernutrition in early childhood, is a recalcitrant problem in resource constrained settings. The underlying causes of growth failure are multifactorial, but persistent and recurrent infection and inflammation of the gastrointestinal tract and immune activation, a condition commonly referred to as environmental enteropathy, is an important contributor. A highly enriched 13C-Sucrose Breath Test, a measure of sucrase-isomaltase activity, will be evaluated as a non-invasive biomarker of environmental enteropathy, and more specifically of intestinal brush border enzyme activity in 6 resource poor countries (Bangladesh, India, Jamaica, Kenya, Peru and Zambia) in 100 volunteers aged 12-15 months (total n=600) and evaluated relative to the lactose rhamnose test and linear and ponderal growth over a 3-6 month period following biomarker assessment. Field usability will also be assessed.


Description:

Environmental enteropathy is associated with linear and ponderal growth shortfalls in young children in resource constrained settings. However, the physiological alterations of intestinal function that accompany both the demonstrable evidence of inflammation and architectural changes seen in biopsies from effected children have yet to be elucidated, and this knowledge gap limits the development of effective strategies to optimally manage the condition. Furthermore, a limited number of non-invasive assays exist with which to assess the presence of environmental enteropathy in low resource settings. This study aims 1) to determine if sucrose-isomaltase enzyme is altered in children with environmental enteropathy by using a 13C-Sucrose breath test 2) to determine if the test is able to be employed in resource limited settings.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date December 2022
Est. primary completion date July 1, 2022
Accepts healthy volunteers
Gender All
Age group 12 Months to 15 Months
Eligibility Inclusion Criteria: All children will be recruited and enrolled through convenience sampling, either at the community level (if the study site has previously censused the community) or through child clinic visits. Exclusion Criteria: 1. Severe acute malnutrition 2. HIV positive 3. Weight for height Z >+2 4. Known medical illness contributing to growth failure

Study Design


Locations

Country Name City State
Australia Flinders University Adelaide
Bangladesh Nutrition and Clincial Services Division, icddr, b Dhaka
India CBCI Society for Medical Education, St John's Research Institute Bengaluru
Jamaica Tropical Metabolism Research Unit, University of West Indies Kingston
Kenya Masinde Muliro University of Science and Technology Kakamega
Peru Investigaciones Biomedicas, Asociacion Benefica PRISMA Iquitos
United Kingdom Scottish Universities Environmental Research Centre East Kilbride
Zambia Tropical Gastroenterology & Nutrition Ltd Lusaka
Zambia Tropical Diseases Research Centre Ndola

Sponsors (12)

Lead Sponsor Collaborator
University of Virginia Asociacion Benefica Prisma, Flinders University, Gastroenterology Services, Ltd., International Atomic Energy Agency, International Centre for Diarrhoeal Disease Research, Bangladesh, Mmust Masinde Muliro University of Science and Technology, Scottish Universities Environmental Research Centre, St. John's Research Institute, The University of The West Indies, Tropical Diseases Research Centre, Zambia, University of Michigan

Countries where clinical trial is conducted

Australia,  Bangladesh,  India,  Jamaica,  Kenya,  Peru,  United Kingdom,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Other Reproducibility of the 13C-SBT test , percent of dose recovered in first 90 minutes We will assess the coefficient of variation and correlation coefficient between repeated cumulative percent of dose recovered at 90 minutes post administration on separate SBT tests administered one week apart done on the same child (Peru site only). Six months from the enrollment of the last subject
Other Reproducibility of the 13C-SBT test, time to 50% area under the curve of 13C tracer, expressed in minutes We will assess the coefficient of variation and correlation coefficient between repeated SBT tests 7 days apart as assessed by the time to 50% area under the curve of 13C tracer, expressed in minutes from the same child (Peru site only). Six months from the enrollment of the last subject
Other Epidemiologic factors that influence 13C-SBT measure, percent of dose recovered at 90 minutes Determine if significant associations exist between 13C-SBT measured as cumulative percent of dose recovered at 90 minutes post administration and the WAMI index.The WAMI index is a previously validated composite index of environmental variables to create a index that expresses the socioeconomic and physical environment in diverse geographical contexts (PMID 24656134) Six months from the enrollment of the last subject
Other Epidemiologic factors that influence 13C-SBT measure, time to 50% AUC recovered Determine if significant associations exist between 13C-SBT measured as the time to recovery of 50% of the administered tracer and the WAMI index. The WAMI index is a previously validated composite index of environmental variables to create a index that expresses the socioeconomic and physical environment in diverse geographical contexts ((PMID 24656134). Six months from the enrollment of the last subject
Primary Comparison of SBT to Lactulose rhamnose (LR) test-% dose 90 min The 13C-SBT (cumulative percent of dose recovered at 90 minutes post administration) will be compared to LR ratio (the ratio of the percent recovery of administered lactulose and mannitol) 6 months after enrollment is completed
Primary Comparison of SBT to Lactulose rhamnose (LR) test- time to 50% recovery The 13C-SBT (time to 50% area under the curve of 13C tracer, expressed in minutes ) will be compared to LR ratio (the ratio of the percent recovery of administered lactulose and mannitol) 6 months after enrollment is completed
Primary Correlation of SBT (% recovery at 90 minutes) to Lactulose rhamnose (LR) test-Lactulose recovery The 13C-SBT (cumulative percent of dose recovered at 90 minutes post administration) will be compared to the percent lactulose recovery at 90 minutes post administration 6 months after enrollment is completed
Primary Correlation of SBT (time to 50% recovery) to Lactulose rhamnose (LR) test-Lactulose recovery The 13C-SBT (time to 50% area under the curve 13C tracer, expressed in minutes) will be compared to the percent lactulose recovery at 90 minutes post administration 6 months after enrollment is completed
Primary Correlation of SBT (% dose recovered at 09 minutes) to Lactulose rhamnose (LR) test-Mannitol recovery The 13C-SBT (cumulative percent of dose of 13C recovered at 90 minutes post administration) will be compared to percent mannitol recovery 6 months after enrollment is completed
Primary Correlation of SBT (time to recovery of 50% of dose) to Lactulose rhamnose (LR) test-Mannitol recovery The 13C-SBT (time to 50% area under the curve 13C tracer, expressed in minutes) will be compared to percent mannitol recovery 6 months after enrollment is completed
Primary Characterize the relationship between SBT (% of dose recovered at 90 min) and baseline childhood anthropometrics (attained length) We will compare results of the SBT test expressed as cumulative percent of dose recovered at 90 minutes post administration and LAZ (length for age Z-score as defined by 2006 World Health Organization norms, cross-sectional) 6 months after enrollment is completed
Primary Characterize the relationship between SBT (time to recovery of 50% of dose) and baseline childhood anthropometrics (attained length) We will compare results of the SBT test expressed as time to 50% area under the curve 13C tracer, expressed in minutes and LAZ (length for age Z-score as defined by 2006 World Health Organization norms, cross-sectional) 6 months after enrollment is completed
Primary Characterize the relationship between SBT and childhood anthropometrics (attained weight) We will compare results of the SBT test expressed as the cumulative percent of dose recovered at 90 minutes post administration and WAZ (weight for age Z-score as defined by 2006 World Health Organization norms, cross-sectional) 6 months after enrollment is completed
Primary Characterize the relationship between SBT and childhood anthropometrics (attained weight for height) We will compare results of the SBT test expressed as time to 50% area under the curve 13C tracer, expressed in minutes and WAZ (weight for age Z-score as defined by 2006 World Health Organization norms, cross-sectional) 6 months after enrollment is completed
Primary Characterize the relationship between SBT (time to 50% recovery of 13C) and childhood linear growth, 3 months We will compare values for the 13C-SBT expressed as time to 50% area under the curve 13C tracer, expressed in minutes and change in length for age Z score (WHO 2006 reference standards) over the subsequent 3 months 6 months after enrollment is completed
Primary Characterize the relationship between SBT and childhood linear growth, 6 months We will compare values for the 13C-SBT expressed as time to 50% area under the curve 13C tracer, expressed in minutes and change in length for age Z score (WHO 2006 reference standards) over the subsequent 6 months 6 months after enrollment is completed
Primary Characterize the relationship between SBT (% dose recovered at 90 min)and childhood linear growth, 3 months We will compare the 13C-SBT tests results (cumulative percent of dose recovered at 90 minutes post administration) and change in LAZ over the subsequent 3 months 6 months after enrollment is completed
Primary Characterize the relationship between SBT and childhood linear growth We will compare the 13C-SBT tests results (cumulative percent of dose recovered at 90 minutes post administration) and change in LAZ over the subsequent 6 months 6 months after enrollment is completed
Secondary Assess the relationship between the 13C-SBT (% recovery 90min) and fecal myeloperoxidase Compare fecal myeloperoxidase concentration (ng/mL) with 13SBT (% of cumulative dose recovered at 90 minutes, expressed as %) Six months from the enrollment of the last subject
Secondary Assess the relationship between SBT ( time to recovery of 50% of the 13C-tracer) and fecal myeloperoxidase Compare fecal myeloperoxidase concentration (ng/mL) with 13SBT (time to recovery of 50% of the administered 13C tracer, measured in minutes) Six months from the enrollment of the last subject
Secondary Assess the relationship between the 13C-SBT (% recovery 90 min) and serum fatty acid binding protein Compare serum fatty acid binding protein concentration (ng/mL), with 13SBT as assessed by % of administered dose recovered at 90 minutes Six months from the enrollment of the last subject
Secondary Assess the relationship between the 13C-SBT (time to 50% recovery) and serum fatty acid binding protein concentration Compare serum fatty acid binding protein concentration (ng/mL) with 13SBT as measured by the time (in minutes) to the recovery of 50% of the administered dose of 13C. Six months from the enrollment of the last subject
Secondary Assess the relationship between the 13C-SBT (time to 50% recovery) and kynurenine tryptophan ratio Compare time to recovery of 50% of 13C probe of SBT with kynurenine tryptophan ratio (molar ratio of KT multiplied by 1000) Six months from the enrollment of the last subject
Secondary Assess the relationship between the 13C-SBT (% recovery at 90 minutes) and kynurenine tryptophan ratio, Compare 13C SBT as measured by % recovery of 13C probe at 90 minutes with kynurenine tryptophan ratio Six months from the enrollment of the last subject
Secondary Assess the relationship between the 13C-SBT as assessed by percent of 13C tracer recovered in at 90 minutes and fecal alpha-antitrypsin concentration Compare 13CSBT as measured by the percent of tracer recovered at 90 minutes with fecal anti-trypsin concentration (mg/g) Six months from the enrollment of the last subject
Secondary Assess the relationship between the 13C-SBT as measured by the time to 50% recovery of 13C and fecal alpha-antitrypsin Compare 13C SBT as measured by the time to 50% recovery of 13C with fecal anti-trypsin concentration (mg/g) Six months from the enrollment of the last subject
See also
  Status Clinical Trial Phase
Completed NCT05012592 - Reducing Malnutrition and Helminthic Infectious Disease Among Primary School Children by the School Nurses N/A
Completed NCT04216043 - Milk Matters in Malnutrition, is it the Lactose or Dairy Protein? N/A
Enrolling by invitation NCT05603793 - YoUng Adolescents' behaViour, musculoskeletAl heAlth, Growth & Nutrition
Completed NCT03573713 - Decreasing Stunting by Reducing Maternal Depression in Uganda: A Cluster Randomized Controlled Trial (CRCT) for Improved Nutrition Outcomes N/A
Not yet recruiting NCT05792514 - The Reliable Nutritional Risk Screening Tools
Enrolling by invitation NCT03355313 - Use of Low-level Laser Therapy on Children Aged One to Five Years With Energy-protein Malnutrition N/A
Completed NCT05551819 - Acceptability of a Microbiome-directed Food in Young Children With Acute Malnutrition N/A
Completed NCT04101487 - Cash Transfers to Increase Dietary Diversity in Grand Gedeh County, Liberia N/A
Active, not recruiting NCT05571280 - Community-based, Controlled, Open-label, Cluster-randomized Trial for the Reduction of Chronic Malnutrition in Children Under Two Years of Age, With Three Intervention Arms Grouped by Clusters, in Two Provinces in Southern Angola, Huíla and Cunene. N/A
Withdrawn NCT05437068 - Nutritional Supplementation in Children at Risk of Undernutrition N/A
Recruiting NCT05442424 - Keiki (Pediatric) Produce Prescription (KPRx) Program Hawaii N/A
Completed NCT03454100 - Community Resilience to Acute Malnutrition N/A
Completed NCT04896996 - The Effect of Continuous Egg Supplement on Personalized Nutri-omics in Primary School Children (SI-EGG STUDY) N/A
Not yet recruiting NCT06049680 - Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients Phase 4
Recruiting NCT06382857 - Effectiveness of a Microbiome-directed Food to Promote Programmatic and Sustained Nutritional Recovery Among Children With Uncomplicated Acute Malnutrition N/A
Recruiting NCT05269992 - Childrens Real Food Tolerance Study N/A
Active, not recruiting NCT05123378 - Liberia National Community Health Assistant (NCHA) Program and Under-five Mortality N/A
Completed NCT04688515 - Effectiveness of a Positive Deviance Program in Reducing Childhood Undernutrition N/A
Not yet recruiting NCT04810468 - Study of Malnutrition in Primary School Children N/A
Completed NCT04334538 - Effect of an Alternative RUTF on Intestinal Permeability in Children With Severe Acute Malnutrition N/A